LTR Pharma Limited (AU:LTP) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LTR Pharma Limited’s Director, Lee Rodne, has been granted 100,000 unlisted options at an exercise price of $2.52, set to expire in December 2028. This change reflects shareholder approval during the company’s 2024 Annual General Meeting. Such updates may influence investor perceptions and market activity around LTR Pharma’s stock.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue